Skip to Main Content

Paper Details

MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
Nat Commun
23
2022
Author NameAffiliation
Pavlos MsaouelThe University of Texas MD Anderson Cancer Center
Bogdan CzerniakThe University of Texas MD Anderson Cancer Center
Eleni EfstathiouThe University of Texas MD Anderson Cancer Center
Thai H HoMayo Clinic
Jianjun ZhangThe University of Texas MD Anderson Cancer Center
Linghua WangThe University of Texas MD Anderson Cancer Center
Linghua WangThe University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS)
  • 1 - 7

Datasets

Release 1.2